Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663158 | 0.82 | SMN1; SMN2 (0.39) | ALDH1A1HPGDKDM4ETSHR | |
| SCHEMBL20931265 | 0.80 | ALDH1A1 (0.40) | ALDH1A1HPGDHSD17B10LMNAALOX15 | |
| SCHEMBL1148993 | 0.79 | SOAT1 (0.46) | ALDH1A1HPGDHSD17B10LMNAALOX15 | |
| SCHEMBL141446 | 0.78 | ALDH1A1 (0.53) | ALDH1A1HPGDHSD17B10LMNAALOX15 | |
| SCHEMBL3287811 | 0.77 | ALDH1A1 (0.37) | ALDH1A1HSD17B10LMNAALOX15MGAM | |
| SCHEMBL9364972 | 0.77 | MGAM (0.44) | ALDH1A1HPGDHSD17B10LMNAALOX15 | |
| SCHEMBL10436321 | 0.77 | ALDH1A1 (0.37) | ALDH1A1HSD17B10LMNAALOX15MGAM | |
| SCHEMBL16046938 | 0.77 | ALDH1A1 (0.37) | ALDH1A1HPGDHSD17B10LMNAALOX15 | |
| Ammonia Solution, Strong SCHEMBL28791130 | 0.76 | ALDH1A1 (0.50) | ALDH1A1HPGDHSD17B10LMNAALOX15 | |
| SCHEMBL8800602 | 0.76 | ALDH1A1 (0.50) | ALDH1A1HPGDHSD17B10LMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025136936-A1 | AGONISTS OF TREM2 ACTIVITY | MERCK SHARP & DOHME LLC (US) | 2025-06-26 | — | — | WO | disclosed |
| US-8030317-B2 | cancerous hyperproliferative disorders; 3-(2,3-dihydroxypropyl)-5-(2-fluoro-4-iodophenylamino)-6,8-dimethylpyrido[4,3-d]pyrimidine-4,7(3H,6H)-dionep; 5-(4-bromo-2-fluorophenylamino)-3-(2,3-dihydroxypropyl)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-04 | — | — | US | disclosed |
| US-8030317-B2 | cancerous hyperproliferative disorders; 3-(2,3-dihydroxypropyl)-5-(2-fluoro-4-iodophenylamino)-6,8-dimethylpyrido[4,3-d]pyrimidine-4,7(3H,6H)-dionep; 5-(4-bromo-2-fluorophenylamino)-3-(2,3-dihydroxypropyl)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20080255160-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080255160-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| CN-1118464-C | Noval pyrimidine derivatives and process and preparing thereof | YUHAN CORP (KR) | 2003-08-20 | — | — | CN | disclosed |
| EP-1015444-B1 | PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP LTD (KR) | 2003-05-28 | — | — | EP | disclosed |
| US-6352993-B1 | ANTIULCER AGENTS | YUHAN CORPORATION (KR) | 2002-03-05 | — | — | US | disclosed |
| EP-1015444-A1 | NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION, LTD. (KR) | 2000-07-05 | — | — | EP | disclosed |
| CN-1251586-A | Noval pyrimidine derivatives and process and preparing thereof | YUHAN CORP (KR) | 2000-04-26 | — | — | CN | disclosed |
| WO-1998043968-A1 | NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 1998-10-08 | — | — | WO | disclosed |
| WO-1991018887-A1 | DIAMINOPYRIMIDINE COMPOUNDS | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1991-12-12 | — | — | WO | disclosed |
| US-4820708-A | ANTISECRETORY AGENTS; GASTROINTESTINAL DISORDERS | SMITH KLINE & FRENCH LABORATORIES (GB) | 1989-04-11 | — | — | US | disclosed |
| US-4777172-A | ANTIGASTRIC ACID SECRETORY AGENT | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-10-11 | — | — | US | disclosed |
| EP-0198583-A1 | Heterocyclic compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255160-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | ALDH1A1 1559/4885HPGD 502/4885HSD17B10 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.